ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs Through Clinical Development
Oversubscribed Series C welcomes multiple new investors September 04, 2024 08:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR…